Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells (Q39404720)

11 September 2017

title

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells (English)

1 reference

11 September 2017

1 reference

T Martinsson

8

0 references

author name string

C Schönherr

1

1 reference

11 September 2017

K Ruuth

2

1 reference

11 September 2017

S Kamaraj

3

1 reference

11 September 2017

C-L Wang

4

1 reference

11 September 2017

H-L Yang

5

1 reference

11 September 2017

V Combaret

6

1 reference

11 September 2017

A Djos

7

1 reference

11 September 2017

J G Christensen

9

1 reference

11 September 2017

R H Palmer

10

1 reference

11 September 2017

B Hallberg

11

1 reference

11 September 2017

language of work or name

English

0 references

publication date

30 January 2012

1 reference

11 September 2017

1 reference

11 September 2017

volume

31

1 reference

11 September 2017

issue

50

1 reference

11 September 2017

page(s)

5193-5200

1 reference

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Neuroblastoma: biological insights into a clinical enigma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Overall genomic pattern is a predictor of outcome in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

ArrayCGH-based classification of neuroblastoma into genomic subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Anaplastic lymphoma kinase: signalling in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Modulation of N-myc expression alters the invasiveness of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Targeted expression of MYCN causes neuroblastoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Myc proteins as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Protein kinase signaling networks in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Crizotinib--latest champion in the cancer wars?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Sensitive detection of numerical and structural aberrations of chromosome 1 in neuroblastoma by interphase fluorescence in situ hybridization. Comparison with restriction fragment length polymorphism and conventional cytogenetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Proteasome inhibitors: valuable new tools for cell biologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Anaplastic lymphoma kinase expression in neuroblastomas and its relationship with genetic, prognostic, and predictive factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

ALK and NSCLC: Targeted therapy with ALK inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.12

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.12

1 reference

11 September 2017

1 reference